Business Context and Reporting Period
This Form 8-K Current Report was filed by cbdMD, Inc. on September 22, 2023. The filing addresses a corporate governance event regarding the adjournment of a Special Meeting of Shareholders originally scheduled for September 22, 2023.
Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is limited to reporting a procedural corporate event.
Material Changes
The primary material change reported is the adjournment of the Special Meeting of Shareholders from September 22, 2023, to October 26, 2023. The Company determined that there were insufficient votes to approve the proposal described in the Proxy Statement filed on August 11, 2023, necessitating additional time to solicit votes from holders of Series A Preferred Stock.
Outlook, Risks, and Management Commentary
- Management Action: The Company will continue to solicit votes from shareholders during the adjournment period.
- Proposal Status: No changes have been made to the proposal to be voted on.
- Shareholder Action: Proxies previously submitted will be voted at the reconvened meeting unless revoked. Shareholders who have already voted do not need to recast their votes unless they wish to change them.
- Logistics: The reconvened meeting will be held virtually on October 26, 2023, at 1:00 p.m. Eastern Time. The record date remains August 1, 2023.
Key Facts for Investor Verification
- Verify the specific proposal details in the Proxy Statement filed on August 11, 2023, as the outcome remains pending.
- Confirm the voting status of Series A Preferred Stock holders, as their votes were critical to the initial failure to approve the proposal.
- Note that the filing explicitly states the information is furnished and not "filed" for purposes of Section 18 of the Exchange Act, limiting liability for forward-looking statements within the press release.
- Check for any subsequent filings regarding the outcome of the meeting on October 26, 2023.